| 000 | 01773 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250518081932.0 | ||
| 264 | 0 | _c20210111 | |
| 008 | 202101s 0 0 eng d | ||
| 022 | _a1098-6596 | ||
| 024 | 7 |
_a10.1128/AAC.01816-19 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCoppi, Marco | |
| 245 | 0 | 0 |
_aCeftazidime-Avibactam Resistance Associated with Increased _h[electronic resource] |
| 260 |
_bAntimicrobial agents and chemotherapy _c03 2020 |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAnti-Bacterial Agents _xpharmacology |
| 650 | 0 | 4 |
_aAzabicyclo Compounds _xpharmacology |
| 650 | 0 | 4 |
_aBacterial Proteins _xgenetics |
| 650 | 0 | 4 |
_aCeftazidime _xpharmacology |
| 650 | 0 | 4 |
_aDNA Transposable Elements _xgenetics |
| 650 | 0 | 4 | _aDrug Combinations |
| 650 | 0 | 4 |
_aDrug Resistance, Multiple, Bacterial _xgenetics |
| 650 | 0 | 4 |
_aEscherichia coli _xgenetics |
| 650 | 0 | 4 |
_aGene Dosage _xgenetics |
| 650 | 0 | 4 |
_aGenome, Bacterial _xgenetics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aKidney Transplantation _xadverse effects |
| 650 | 0 | 4 |
_aKlebsiella Infections _xdrug therapy |
| 650 | 0 | 4 |
_aKlebsiella pneumoniae _xdrug effects |
| 650 | 0 | 4 | _aMicrobial Sensitivity Tests |
| 650 | 0 | 4 |
_aPlasmids _xgenetics |
| 650 | 0 | 4 |
_aPorins _xgenetics |
| 650 | 0 | 4 | _aWhole Genome Sequencing |
| 650 | 0 | 4 |
_abeta-Lactamase Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_abeta-Lactamases _xgenetics |
| 700 | 1 | _aDi Pilato, Vincenzo | |
| 700 | 1 | _aMonaco, Francesco | |
| 700 | 1 | _aGiani, Tommaso | |
| 700 | 1 | _aConaldi, Pier Giulio | |
| 700 | 1 | _aRossolini, Gian Maria | |
| 773 | 0 |
_tAntimicrobial agents and chemotherapy _gvol. 64 _gno. 4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1128/AAC.01816-19 _zAvailable from publisher's website |
| 999 |
_c30544499 _d30544499 |
||